Abstract:There has been a major increase in Type 2 diabetes and obesity in many countries, and this will lead to a global public health crisis, which not only impacts on the quality of life of individuals well but also places a substantial burden on healthcare systems and economies. Obesity is linked to not only to type 2 diabetes but also cardiovascular diseases, musculoskeletal disorders, and certain cancers, also resulting in increased medical costs and diminished quality of life. A number of studies have linked changes in gut in obesity development. Dysbiosis, a deleterious change in gut microbiota composition, leads to altered intestinal permeability, associated with obesity and Type 2 diabetes. Many factors affect the homeostasis of gut microbiota, including diet, genetics, circadian rhythms, medication, probiotics, and antibiotics. In addition, bariatric surgery induces changes in gut microbiota that contributes to the metabolic benefits observed post-surgery. Current obesity management strategies encompass dietary interventions, exercise, pharmacotherapy, and bariatric surgery, with emerging treatments including microbiota-altering approaches showing promising efficacy. While pharmacotherapy has demonstrated significant advancements in recent years, bariatric surgery remains one of the most effective treatments for sustainable weight loss. However, access to this is generally limited to those living with severe obesity. This underscores the need for non-surgical interventions, particularly for adolescents and mildly obese patients. In this comprehensive review, we assess longitudinal alterations in gut microbiota composition and functionality resulting from the two currently most effective anti-obesity treatments: pharmacotherapy and bariatric surgery. Additionally, we highlight the functions of gut microbiota, focusing on specific bacteria, their metabolites, and strategies for modulating gut microbiota to prevent and treat obesity. This review aims to provide insights into the evolving landscape of obesity management and the potential of microbiota-based approaches in addressing this pressing global health challenge.

Gut microbiota composition and its effects on obesity and insulin resistance

Dietary Fiber and Its Potential Role in Obesity: A Focus on Modulating the Gut Microbiota

Importance of gut microbiota in obesity

Gut microbiota, obesity and metabolic disorders

Gut microbiota as a factor in epigenetic programming of the phenotypes of obesity and type 2 diabetes mellitus. Review

Involvement of gut microbiota in the development of low-grade inflammation and type 2 diabetes associated with obesity

Gut microbiota in obesity and metabolic disorders

The Gut Microbiome as a Target for the Treatment of Type 2 Diabetes

Exploring the Gut Microbiota: Key Insights into Its Role in Obesity, Metabolic Syndrome, and Type 2 Diabetes

Metabolites Linking the Gut Microbiome with Risk for Type 2 Diabetes

Influence of the human intestinal microbiome on obesity and metabolic dysfunction

Is the Gut Microbiota a New Factor Contributing to Obesity and Its Metabolic Disorders?

Impact of Gut Microbiota on Obesity, Diabetes, and Cardiovascular Disease Risk

Interactions between host genetics and gut microbiome in diabetes and metabolic syndrome

Understanding the role of the human gut microbiome in overweight and obesity

The Epigenetic Connection Between the Gut Microbiome in Obesity and Diabetes

Gut microbiota and obesity: New insights

The Role of Gut Microbiota in Obesity and Type 2 and Type 1 Diabetes Mellitus: New Insights into “Old” Diseases

Relationship between gut microbiota, obesity and diabetes

Gut microbiota and therapy for obesity and type 2 diabetes

The role of Gut Microbiota in the development of obesity and Diabetes